header logo image


Page 14«..10..13141516..2030..»

Archive for April, 2020

How to make sure you are getting enough vitamins: foods, supplements and everything you need to know – The National

Tuesday, April 21st, 2020

Our lifestyles have changed dramatically in recent weeks. As we all do our bit to stem the spread of Covid-19 by staying at home, our sleeping, eating and working patterns have been thrown into disarray. Most of us are moving less, getting less access to fresh air and less exposure to sunlight.

This may mean that our bodies are not receiving the essential minerals and vitamins they need. And getting the right balance of nutrients is essential to keeping our bodies functioning properly all the more important when we are all trying to ensure our immune systems are strong.

Vitamin D, in particular, might be a problem at the moment, as the body relies on sunlight to produce it. People currently isolating in apartments, with no access to outside space, need to be conscious of a potential deficiency.

Vitamin D is known as the sunshine vitamin, since it is made by the body after being in the sun. Vitamin D helps the body absorb calcium. You need calcium for the normal development and maintenance of healthy teeth and bones. It also helps maintain proper blood levels of calcium and phosphorus. Ten to 15 minutes of sunshine, three times a week, is enough to produce the body's requirement of vitamin D for most people at most latitudes, explains Dr. Nadine Aoun, clinical dietician at Medcare.

Try to eat a wide variety of colourful vegetables every day and follow a balanced diet

While it is difficult to get enough vitamin D from food sources alone, Dr Mariam Khalfan Al Suwaidi, head of Healthpoints department of dermatology, highlights some foods that can help. Foods high in vitamin D include oily fish, mushrooms, eggs and dairy products, and vitamin-D-fortified foods. Also try to eat a wide variety of colourful vegetables every day and follow a balanced diet to ensure you get all vitamins and minerals.

Given the importance of Vitamin D, and the struggles that many people have getting it in sufficient quantities, particularly under the current circumstances, Natasha Rudatsenko, founder of the online health and fitness platform, Health Nag, recommends taking a supplement.

It is absolutely essential, she says. Vitamin D contributes a lot to our overall immunity as well as hormonal balance, so this is something I recommend taking for absolutely everyone. 5,000 to 7,000 IU is a good daily dose. Go for its active form, the one that is most bioavailable to our body, Vitamin D3. Its a fat-soluble vitamin, so it is good to take it with something fatty. The most convenient way of getting vitamins, in my opinion, is still http://www.Iherb.com."

As a general consensus, medical experts recommend that you do not overdo the vitamin supplements. With some vitamins, too much can be as harmful as too little. The aim is to try to achieve a balanced and healthy diet, before you go reaching for the supplements.

Dr Aoun offers a breakdown of the vitamins you need, and some of the foods you should be consuming to get them:

Vitamin A: Helps form and maintain healthy teeth, bones, soft tissue, mucus membranes and skin. Found in beef, liver, eggs, shrimp, fish, fortified milk, sweet potatoes, carrots, pumpkins, spinach and mangoes.

Vitamin B6: Helps form red blood cells and maintain brain function. It also plays an important role in the proteins that are part of many chemical reactions in the body. Found in meat, fish, poultry, legumes, tofu and other soy products, and bananas.

Vitamin B12: Like the other B vitamins, this is important for metabolism. It also helps form red blood cells and maintain the central nervous system. Found in meat, poultry, fish, milk, cheese, fortified soy milk and cereals.

Vitamin C: An antioxidant that promotes healthy teeth and gums. It helps the body absorb iron and maintain healthy tissue. It is also essential for wound healing. Found in citrus fruit, potatoes, broccoli, bell peppers, spinach, strawberries, tomatoes and Brussels sprouts.

Vitamin E: Also an antioxidant. It helps the body form red blood cells and use vitamin K. Found in vegetables oils, leafy green vegetables, whole grains and nuts.

Vitamin K: Without this, blood would not stick coagulate. Found in spinach, broccoli and kale.

Biotin (B7): Essential for the metabolism of proteins and carbohydrates, and in the production of hormones and cholesterol. Found in whole grains, eggs, soy beans and fish.

Niacin (B3): A B vitamin that helps maintain healthy skin and nerves. Found in meat, poultry, fish, fortified and whole grains, mushrooms and potatoes.

Folate: Works with vitamin B12 to help form red blood cells. It is needed for the production of DNA, which controls tissue growth and cell function. Found in fortified grains and cereals, asparagus, spinach, broccoli, legumes (black-eyed peas and chickpeas) and orange juice.

Pantothenic acid: Essential for the metabolism of food. Found in chicken, whole grains, broccoli, avocados and mushrooms.

Riboflavin (vitamin B2): Important for body growth and the production of red blood cells. Found in milk, yogurt, cheese, whole and enriched grains, and cereals.

Thiamine (vitamin B1): Helps the body cells change carbohydrates into energy. Found in soy milk and watermelon.

Updated: April 21, 2020 02:24 PM

See the rest here:
How to make sure you are getting enough vitamins: foods, supplements and everything you need to know - The National

Read More...

COVID-19 and civil aviation – The Lawyer’s Daily

Tuesday, April 21st, 2020

Severe acute respiratory syndrome, coronavirus 2, SARS-CoV-2 (COVID-19), a betacoronavirus, with a fulminant atypical pneumonia presentation, sharing a high sequence identity with that of SARS-CoV-1 and bat-SARS-like coronavirus the global pandemic of 2020 has affected every continent except Antarctica where no humans live.

The convention on International Civil Aviation (Convention), International Civil Aviation Organization (ICAO), U.S., Regulation (EC) No. 216/2008, Regulation (EC) No. 216/2008, Canadian and other law must adapt to reflect the 21st century. Airworthiness is the measure of an aircraft being suitable for a safe flight. Aerosol and fomite (objects or materials that are likely to carry infection, such as elevator buttons or bathroom taps) transmission of COVID-19 is plausible because viruses can propagate or function properly and are infectious in aerosols for hours and on surfaces for days.

Dr. Tedros Adhanom Ghebreyesus, the World Health Organizations (WHO) Director General and Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases, indicated that the RNA viruses emanated from China, have mutated and are transmitted from human to human as they are what we call RNA viruses, or those that have mainly RNA as their genetic material (one being COVID-19), in comparison to DNA. RNA viruses mutate constantly and do not have the mechanisms to correct these mistakes like those of human cells, which replicate with DNA. The mistakes appear in the genetic sequence coding for the corona protein with a total length of 1,273 amino acids showing 27 amino acid substitutions (a mutation).

Since 2002, COVID-19 has been a perfect example where multiple genes of a virus have exceptionally high mutation rates since its origin, causing it to be more severe in some cases or transmit more easily and depending on the temperature. According to scientists, the coronavirus thrives in cold and dry conditions and may not be a stranger next winter if it wanes over the summer.

Not long ago, accurate RNA detection was decisive in the diagnosis of COVID-19 through the COVID-19 RT-PCR test, a real time reverse transcription polymerase chain reaction, for the qualitative detection of the SARS-CoV-2 RNA, and next generation sequencing has facilitated the identification of the pathogen. The amino acid sequence of COVID-19 is different from other coronaviruses, particularly in the regions of 1ab polyprotein and surface glycoprotein or S protein.

The first novel coronavirus genome sequence of COVID-19 was discovered on Jan. 10 and was deposited in the GenBank database and uploaded to the Global Initiative on Sharing All Influenza Data. By Jan. 20, Thailand, Japan and South Korea confirmed all cases were exported from China. France reported its first case on Jan. 24 and Germany reported cases related to an individual visiting from China.

Brazilian scientists conducted preliminary studies, which showed the virus in Brazil to be different from the one observed in Wuhan, China by three mutations, two of which draw the virus close to the strain detected in the Bavarian region of Germany.

COVID-19 spread so quickly throughout Wuhan because it is a densely populated area. With international business travellers and tourists leaving China, individuals asymptomatic or ill with the virus transmitted to others on airplanes, which were densely packed and often delayed, and with many having no ventilation system. When airplanes were ventilated, the bleed air supply was a mixture of fresh, cold air fromoutside and recirculated air from the cabin. The airworthiness in aircrafts were compromised, violating the U.S. Code of Federal Regulations, 14 CFR s. 91.7 civil aircraft airworthiness: a) No person may operate a civil aircraft unless it is in an airworthy condition.

The Canadian counterpart is the Canadian Aviation Regulations, SOR/96-433 (s. 521.30), which states: The Minister shall establish, in respect of an aeronautical product, a certification basis consisting of: a) subject to subsections (2) and (5), the applicable standards of airworthiness referred to in s. 521.31 that are in force on the date of application for the type certificate.

Regulation (EC) No. 216/2008 of the European Parliament and of the Council of Feb. 20, 2008 included the common rules in the field of civil aviation and established a European Aviation Safety Agency, repealing Council Directive 91/670/EEC, Regulation (EC) No. 1592/2002 and Directive 2004/36/E. Currently, the United Kingdom is a member state of the European Aviation Safety Agency, Article 20, until Dec. 31, when the U.K. Civil Aviation Authority will assume responsibility over the airworthiness of aircraft in the U.K.

Aside from human to human transmission of the virus, which mainly occurs through saliva droplets and direct and indirect contact with surfaces, Dr.Neeltje van Doremalen et al have raised a legitimate concern over aerosol and surface transmission in a study published by the New England Journal of Medicine titled Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.

Their data comprised 10 experimental conditions with the two viruses in five environmental conditions aerosols, plastic, stainless steel, copper and cardboard. The strength to stand or endure SARS-CoV-2 was equivalent to that of SARS-CoV-1 under the study of van Doremalen et al indicating differences of epidemiologic characteristics of SARS-CoV-2 and the latter, which probably come about from other factors such as high viral burden (high numerical expression of the virus quantity in a given volume) in the upper respiratory tract (nose and nasal passages, paranasal sinuses, the pharynx and part of the larynx) and the possibility of individuals affected with asymptomatic SARS-CoV-2 to shed and transmit the virus.

The Convention on International Civil Aviation (Chicago Convention) received its 26th ratification on March 5, 1947. After ratification, the ICAO was born, on April 4, 1947, becoming a specialized agency of the United Nations connected to the Economic and Social Council.

Although Article 14 of the convention defines COVID-19 as a communicable disease, thereby dealing with the prevention of the spread of disease, Article 35, which reflects cargo restrictions, speaks of munitions. In the Cambridge Dictionary, munitions are defined as military weapons guns and bombs as well as implements that take into account a tool or other piece of equipment for doing work or implements of work, which include arms, ammunition, weaponry and defence systems. Blacks Law Dictionary, international law and U.S. statutes do not include communicable diseases under munitions of war.

Given the pandemic, Article 37(e) adoption of international standards and procedures requires a change to reflect certain issues in countries.

With the significant number of cases and the severe implications of the virus, COVID-19 is the biggest public health threat in the world. The Convention on International Civil Aviation, the ICAO, as well as U.S., U.K., Canadian and other law, must give due consideration to the new implications of coronaviruses.

Esther Carenza is a senior law clerk who works primarily in the area of legal-medical research and as a legal-medical consultant. She was also a mentor-supervisor for the Medico-Legal Society of Toronto project at the University of Toronto, Faculty of Law and Osgoode Hall Law School. E-mail her atecarenza1@gmail.com.

Photo credit / blacklight_traceISTOCKPHOTO.COM

Interested in writing for us? To learn more about how you can add your voice toThe Lawyers Daily,contact Analysis Editor Peter Carter atpeter.carter@lexisnexis.caor call 647-776-6740.

The rest is here:
COVID-19 and civil aviation - The Lawyer's Daily

Read More...

6 Things Experts Look For In A High-Quality Hemp Oil – mindbodygreen.com

Tuesday, April 21st, 2020

According to Carl Germano, R.D., CNS, CDN, the author of Road to Ananda: Simple Guide to the Endocannabinoid System, Hemp Phytocannabinoids/CBD, and Your Health, the use of pesticides, herbicides, and genetic modification is not uncommon in the hemp industry. Plus, hemp is a bioaccumulator, meaning it's very efficient at removing toxins and pollutants from the air, water, and soil. (The plant is so good at this that it's actually being used to help clean up dirty environments.) This means that if your hemp is not grown and processed carefully, you might be getting toxins in your extract. Look for an organic, non-GMO product that's been certified from a third party and tested for heavy metals.

Also, if not stored and handled properly, hemp is prone to growing certain kinds of fungi that can produce aflatoxin, a substance that can cause liver damage and other health issues. Yet another reason to buy from a reputable brand that handles the crop properly and tests for aflatoxin.

Read the rest here:
6 Things Experts Look For In A High-Quality Hemp Oil - mindbodygreen.com

Read More...

Purdue starts limited COVID-19 testing in diagnostic lab with Fort Wayne’s Parkview Health – FW Business

Tuesday, April 21st, 2020

WEST LAFAYETTE Purdue University is continuing to lend expertise and resources to help fight the COVID-19 pandemic through increasing Indianas testing capacity for the virus thanks to a partnership with the Indiana State Department of Health and Indiana hospitals.

The Indiana Animal Disease Diagnostic Laboratory (ADDL) located in Purdues College of Veterinary Medicine is working with Fort Wayne-based Parkview Health to start conducting COVID-19 tests for human patients. Testing began after the lab received Clinical Laboratory Improvement Amendments certification to conduct human diagnostic testing, with Parkview agreeing to provide clinical oversight.

Testing will be expanded in collaboration with other hospitals, with all samples sent directly from partner hospitals to the ADDL. To avoid a testing backlog, hospitals interested in working with the ADDL are required to complete the Partnership Inquiry form.

The goal is to turn around results the same day that samples are received in the lab.

The lab was certified in a matter of days after Purdue leaders suggested using the ADDL to conduct tests and address the states limited testing capacity and need for resources. State Health Commissioner Kris Box, M.D., FACOG, said in a recent daily briefing with Gov. Eric Holcomb that resources are still limited for COVID-19 testing in Indiana as the number of cases continues to rise.

The College of Veterinary Medicine has a long history of providing services to protect animal and human health, said Willie Reed, dean of the College of Veterinary Medicine. Providing COVID-19 testing is yet another way to support the citizens of Indiana during this unprecedented public health crisis. The project was shepherded by David Broecker of the Purdue Research Foundation and involves several partners including the foundation, the Indiana State Department of Health, Parkview Hospital, the Purdue community.

Broecker is the chief innovation and collaboration officer for the Purdue Research Foundation.

Dr. Kenitra Hendrix, director of the Animal Disease Diagnostic Laboratory, says the ADDL had a unique opportunity to assist with COVID-19 testing in Indiana because of the labs expertise in providing infectious disease testing and immunity surveillance for animals across the state.

The ADDL is uniquely positioned to contribute skills and expertise in the detection of pathogens to the fight against COVID-19, while maintaining our diagnostic support of animal health and the safety of the food supply, Hendrix said.

Hendrix says the samples are being tested using a PCR (Polymerase Chain Reaction) testing method that the ADDL uses regularly for animal specimens. The ADDL team, working with state health authorities, adjusted its intake and sample processing procedures to gain the necessary certification to use the PCR testing capability on human specimens.

Our team has worked diligently to prepare to perform this testing, Hendrix said. It is rewarding to be able to take on this role in support of the citizens of our state.

The project is a cross-disciplinary, collaborative effort with the Indiana State Department of Health, the Purdue Research Foundation and the Purdue community.

Indiana continues to increase our capabilities and preparedness for rapidly testing patients to support our front-line health care workers, Box said. We are grateful to Purdue and the ADDL for helping to make testing more available for Hoosiers who are helping others during this pandemic.

Parkview Health provided clinical expertise on obtaining a CLIA license and setting up the lab for human testing.

It still takes several days to get results that are sent out to central labs across the country, said Dr. Michael J. Mirro, chief academic research officer at Parkview Health. Even the new tests are limited by supply constraints. What Purdue has done is fantastic and shows the ingenuity associated with creative problem solving. Paired with the significant amount of time invested by the Parkview lab team, we believe this will have a positive impact on the states testing capacity.

The ADDL is a Biosafety Level 2 (BSL-2) facility accredited by the American Association of Veterinary Laboratory Diagnosticians (AAVLD). BSL-2 laboratories are used to study moderate-risk infectious agents or toxins.

Hendrix says that additional partnerships with other hospitals across the state are possible. More information and a form for potential partners are available at https://purdue.vet/covid19testing.

See the rest here:
Purdue starts limited COVID-19 testing in diagnostic lab with Fort Wayne's Parkview Health - FW Business

Read More...

Thinking of adopting a pet during quarantine? Here’s what you need to know – WBNG-TV

Tuesday, April 21st, 2020

(WBNG) -- If you're feeling those isolation blues, finding a new companion could help with loneliness. However, before adopting a pet, the Broome County Humane Society says you need to be prepared.

"Animals cost us something every year outside of just food and the supplies they need. Every year they need vaccines, you have to be prepared for the unexpected, whether you're getting a dog from a shelter or from a breeder, sometimes they have health conditions that you can't anticipate," said Broome County Humane Society Executive Director Karen Matson.

Marvin Diaz, a Vestal resident, adopted a new puppy, Theo, in late March during the pandemic. He says his family planned to have a puppy, but the pandemic still brought a few challenges.

"Going to a vet, that was the only thing. We called the next day after we got them, and they said as of that Friday, veterinary medicine had become a non-essential type of business unless it was for emergency situations," said Diaz.

Diaz says a new puppy need a lot of time and attention that will last beyond any time spent in quarantine.

"I know the next month or so we might be at home, but a dog is going to be around for more than a month or two. This is a long-term commitment and I think that's an important thing to realize," said Diaz.

After the pandemic, the humane society says they're finding ways to help so animals don't have to be returned.

"We have ample food and supplies to help people in need right now, so hopefully the number of animals being turned over for those type of reasons can stay low because we do have some resources to help out," said Matson.

If you're looking to adopt, you can visit the Broome County Humane Society's website.

See the original post:
Thinking of adopting a pet during quarantine? Here's what you need to know - WBNG-TV

Read More...

Quiet beginning to the week – WBRZ

Tuesday, April 21st, 2020

Sun and lower humidity are expected to start the week. The next storm system will move through the area Wednesday night. For the second straight weekend, a very strong tornado occurred just north and east of the local viewing area. An EF-4 tornado struck Walthall County last Sunday. Another powerful twister moved through Lamar County last night. We will await the damage survey from the National Weather Service for a rating. In the local area, there were some spotty hail and wind damage reports.

THE FORECAST:

Today and Tonight: Clouds will at least be a part of skies through Monday morning. More sunshine will become available by afternoon. Temperatures will warm into the upper 70s with light, north winds. With an overnight reading in the low 60s, some passing clouds are expected. Models hint at a passing shower near dawn, but activity should be brief and isolated, if at all.

Up Next: An area of surface high pressure will bring lower dewpoints and pleasantconditions through Tuesday. Temperatures will stay above average through the week, and hover in the low-to-mid80s with lows near 60. The next low pressure system is set to develop and pass to our north late Wednesday and Thursday, which will bring a return to showers and storms along the Gulf Coast. While considerably less robust than the last two storm systems, one or two storms could maintain some strength through the local area Wednesday night. The Storm Prediction Center has parts of Pointe Coupee Parish and southwest Mississippi in a 2/5 slight risk for severe weather. Anotherweak system is poised to move through on Saturday afternoon with just isolated activity.

The Mississippi River: At Baton Rouge, major flood stage continues with a level of 43.7 as of Monday morning. The river is expected to fall very slowly through the next two weeks. The high water is primarily an issue for river traffic and river islands, although some inundation will continue for a few spots north and south of Baton Rouge that are not protected by levees. Unprotected low-lying areas will be flooded and agricultural operations will be impacted on the west side of the river. The grounds of the older part of Louisiana State University's campus become soggy. This includes the area around the Veterinary Medicine building, the Veterinary Medicine Annex, the stadium and ball fields. The city of Baton Rouge and the main LSU campus are protected by levees at this level. The level is also high in New Orleans and the U.S. Army Corps of Engineers has opened the Bonnet Carre Spillway.

THE EXPLANATION:

Northwesterly winds in the upper levels of the atmosphere will maintain drier air and quieter weather over the next two days. A weak disturbance over northwestern Texas on Monday morning could potentially cause an isolated shower around daybreak Tuesday but this chance is fleeting. The next, more substantial storm system will zip across the southern tier on Wednesday. This upper level trough will pull moisture northward through the day. By evening, a surface low pressure reflection will move across Arkansas and north Mississippi with a trailing cold front. This system will take a slightly more northern track, meaning the wind fields will not be quite as favorable for severe weather as the last system. Also, the nighttime passage will leave a little less warmth and instability as well. Still, enough ingredients are showing up on forecast model guidance that one or two strong thunderstorms will be possible, especially north and west of Baton Rouge. Given the non-zero possibility of a strong storm, the Storm Prediction Center has placed areas from McComb to St. Francisville and points north in a slight risk for severe weather. This system will exit on Thursday morning with quiet weather to follow until another weak disturbance arrives on Saturday. At this time, that one looks low impact.

--Josh

The WBRZ Weather Team is here for you, on every platform. Your weather updates can be found on News 2, wbrz.com, and the WBRZ WX App. on Apple and Android devices. Follow WBRZ Weather on Facebook and Twitter for even more weather updates while you are on the go.

More here:
Quiet beginning to the week - WBRZ

Read More...

Veterinary Medicine Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 Cole Reports – Cole of Duty

Tuesday, April 21st, 2020

Parnell

Veterinary Medicine Market: Competitive Landscape

The last chapter of the Veterinary Medicine market research report focuses exclusively on the competitive landscape. It examines the main market players. In addition to a brief overview of the business, analysts provide information on their assessment and development. The list of important products in preparation is also mentioned. The competitive landscape is analyzed by understanding the companies strategies and the initiatives they have taken in recent years to overcome intense competition.

Veterinary Medicine Market: Drivers and Restraints

The report explains the drivers of the future of the Veterinary Medicine market. It assesses the different forces which should have a positive impact on the whole market. Analysts have looked at investments in research and development for products and technologies, which should give players a significant boost. In addition, the researchers undertook an analysis of the evolution of consumer behavior which should have an impact on the cycles of supply and demand in the Veterinary Medicine market. In this research report, changes in per capita income, improvement in the economic situation and emerging trends were examined.

The research report also explains the potential restrictions on the Veterinary Medicine market. The aspects assessed are likely to hamper market growth in the near future. In addition to this assessment, it offers a list of opportunities that could prove lucrative for the entire market. Analysts offer solutions to turn threats and restrictions into successful opportunities in the years to come.

Veterinary Medicine Market: Regional Segmentation

In the following chapters, analysts have examined the regional segments of the Veterinary Medicine market. This gives readers a deeper insight into the global market and allows for a closer look at the elements that could determine its evolution. Countless regional aspects, such as the effects of culture, environment and government policies, which affect regional markets are highlighted.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=21894&utm_source=COD&utm_medium=007

What will the report contain?

Market Dynamics: The report contains important information on influencing factors, market drivers, challenges, opportunities and market trends as part of the market dynamics.

Global Market Forecast: Readers receive production and sales forecasts for the Veterinary Medicine market, production and consumption forecasts for regional markets, production, sales and price forecasts for the Veterinary Medicine market by type and consumption forecasts for the Veterinary Medicine market per application.

Regional Market Analysis: It can be divided into two different sections: one for the analysis of regional production and one for the analysis of regional consumption. Here, analysts share gross margin, prices, sales, production, CAGR, and other factors that indicate the growth of all regional markets examined in the report.

Market Competition: In this section, the report provides information on the situation and trends of competition, including mergers and acquisitions and expansion, the market shares of the three or five main players and the concentration of the market. Readers could also get the production, revenue, and average price shares of manufacturers.

Key Players: The report provides company profiles for a decent number of leading players in the Veterinary Medicine market. It shows your current and future market growth taking into account price, gross margin, income, production, service areas, production locations and other factors.

Complete Report is Available @ https://www.verifiedmarketresearch.com/product/Veterinary-Medicine-Market/?utm_source=COD&utm_medium=007

We also offer customization on reports based on specific client requirement:

1- Free country level analysis for any 5 countries of your choice.

2- Free Competitive analysis of any market players.

3- Free 40 analyst hours to cover any other data points

About us:

Verified market research partners with the customer and offer an insight into strategic and growth analyzes, Data necessary to achieve corporate goals and objectives. Our core values are trust, integrity and authenticity for our customers.

Analysts with a high level of expertise in data collection and governance use industrial techniques to collect and analyze data in all phases. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise and years of collective experience to produce informative and accurate research reports.

Contact us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

Get Our Trending Report

Leather Conditioner Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Tags: Veterinary Medicine Market Size, Veterinary Medicine Market Trends, Veterinary Medicine Market Forecast, Veterinary Medicine Market Growth, Veterinary Medicine Market Analysis

More:
Veterinary Medicine Market 2020 Break Down by Top Companies, Applications, Challenges, Opportunities and Forecast 2026 Cole Reports - Cole of Duty

Read More...

COVID-19 Testing by the ADDL at Purdue University – Purdue Veterinary News

Tuesday, April 21st, 2020

Purdue University is continuing to lend expertise and resources to help fight the COVID-19 pandemic by increasing Indianas testing capacity through the capabilities of the Animal Disease Diagnostic Laboratory at the Purdue University College of Veterinary Medicine. Thanks to a collaborative effort involving Purdue, the Purdue Research Foundation, the Indiana State Department of Health and Indiana hospitals, the ADDL is utilizing its skills and expertise in the detection of pathogens to conduct COVID-19 tests on specimens from partner hospitals with the goal of providing results the same day the samples are received.

The ADDL began COVID-19 testing after obtaining the Clinical Laboratory Improvement Amendments (CLIA) certification required for laboratories performing testing on human samples. This effort does not diminish the ADDLs diagnostic support for animal health and the safety of the food supply, which remains its first priority. Because of limited capacity to perform COVID-19 testing, the ADDL will only accept specimens from pre-approved partner hospitals.

*The ADDL has limited available capacity. Interested Hospitals should complete the Partnership Inquiry form if they wish to be contacted should testing capacity increase.

Follow this link:
COVID-19 Testing by the ADDL at Purdue University - Purdue Veterinary News

Read More...

Thailand begins mass vaccination of horses to curb African Horse Sickness spread – Reuters

Tuesday, April 21st, 2020

Veterinarian Aree Laikul from Kasetsart University's faculty of Veterinary Medicine, vaccinates a horse amid an outbreak of the deadly African Horse Sickness (AHS) in the country, at Farm Mor Por stable in Khao Yai National Park, Nakhon Ratchasima, Thailand April 20, 2020. REUTERS/Jorge Silva

Nakhon Ratchasima (Reuters) - Thailand began vaccinating some 4,000 horses on Monday in a bid to contain the spread of the deadly African Horse Sickness (AHS), a disease that only affects horses and other equine animals.

More than 200 horses in seven provinces have died since the outbreak was first reported earlier this year, the first time the highly infectious AHS virus, transmitted by insects, has appeared in Southeast Asia.

Horse owners in northeastern Nakhon Ratchasima province have installed mosquito nets on stables and conduct regular temperature and health checks, while putting sick horses under quarantine.

The government has also banned the import and export of horses, zebras and related animals.

Veterinarians say if the disease cannot be contained by the mass vaccination, it could wipe out all 11,800 horses in Thailand, where they are kept mostly for racing and leisure riding for tourists and private owners.

Without any prevention, 10 out of 10 horses will contract the virus... nine out of 10 sick horses will die from it, Aree Laikul a veterinarian from Kasetsart Universitys faculty of Veterinary Medicine who is helping the vaccination drive.

There have been no reported cases of AHS in humans, and it is not related to the coronavirus pandemic.

AHS is endemic in the central tropical regions of Africa, from where it spreads regularly to Southern Africa and occasionally to North Africa, according to information from the World Organization for Animal Health.

Editing by Kay Johnson & Simon Cameron-Moore

Continue reading here:
Thailand begins mass vaccination of horses to curb African Horse Sickness spread - Reuters

Read More...

Why the New Coronavirus Affects Some Animals, but Not Others – Smithsonian

Tuesday, April 21st, 2020

In just a few months, the ongoing COVID-19 pandemic has put billions of humans at risk. But as researchers work around the clock to understand SARS-CoV-2, the virus behind the disease, some have begun to worry that countless others may be at stake: animals who could catch the germ from their distant Homo sapiens cousins.

Recent reports of SARS-CoV-2 infecting creatures such as monkeys, dogs, ferrets, domestic cats and even a tiger have raised the possibility that the pathogen could plague other speciesincluding, perhaps, ones already imperiled by other, non-infectious threats.

Though researchers suspect the virus originated in a wild creature such as a bat, they stress that humans remain the virus most vulnerable victims, as well as the hosts most likely to spread the disease from place to place. There is also no evidence that animals are passing the pathogen to people, says Jane Sykes, a veterinarian and animal virus researcher at the University of California, Davis. However, studying the creatures this stealthy virus has affected so far could help scientists understand what makes some speciesbut not otherssusceptible.

Coronaviruses are notoriously indiscriminate infectors. The number of different coronaviruses that exist in the wild number in at least the hundreds, with most likely inhabiting the bodies of bats. On the whole, members of this large family of viruses seem very capable of frequent hops into new species, including humans, making recent detections of SARS-CoV-2 in non-human animals somewhat unsurprising, says Linda Saif, a virologist and animal coronavirus expert at Ohio State University. Already, a commonality in these cases has emerged: the molecular compatibility of the virus with its host.

To infect a cell, a virus must first break in. This encounter typically requires the pathogen to fit itself into a specific molecule, called a receptor, on the surface of its target cell. Its a bit like a key opening a lock. Not all viral keys will work on a given cells lock, but the better the fit, the more easily the virus can gain access.

Unfortunately for humans and our animal relatives, SARS-CoV-2s key, called spike protein, is a multifunctional tool. It homes in on a cellular lock called ACE2a blood pressure-regulating protein thought to be universal among vertebrates, the group that includes mammals, birds, reptiles, amphibians and fish, says Jim Wellehan, a zoologist and microbiology at the University of Floridas College of Veterinary Medicine.

Millions of years of evolution have subtly tweaked the shape of ACE2 in each of these lineages. But in domestic cats and several primates, the regions of ACE2 that bind to SARS-CoV-2s spike protein look nearly or completely identical to the vulnerable human version.

Such molecular similarities may help explain why a cat in Belgium and another in Hong Kong, each under the care of owners who fell ill with COVID-19, reportedly tested positive for the virus in March. During the SARS outbreak that began in 2002, SARS-CoV-1a similar coronavirus that also uses ACE2 to enter cells (albeit less effectively than SARS-CoV-2)also hopped from sick humans into domestic felines.

Sykes says these isolated incidents shouldnt be cause for alarm. Although a recent study in the journal Science corroborated that cats can contract SARS-CoV-2 when experimentally dosed with large amounts of virus, pets probably arent getting seriously sick very often in the real world, she says. (If they were, wed probably know by now.)

The felines most at risk, Sykes says, are probably those in the company of sick owners, who may be exposing their pets to high quantities of viral particles. Even then, infection isnt a guarantee. Another recent study, which has yet to be published in a peer-reviewed journal, found no evidence of the virus in a group of cats and dogs that had spent several weeks cooped up with several SARS-CoV-2-infected humans. Large surveys in places like Hong Kong, the United States and South Korea have borne out similar results: thousands of pet cats, as well as horses and dogs, tested negative for the new coronavirus. (But another studyalso not peer-revieweddid find antibodies against the virus in some feral felines from Wuhan, China, hinting that the animals may have encountered the pathogen before.)

Theres also no evidence that infected cats can shuttle the virus into humans, Sykes says. And while the researchers behind the new Science study noted that cat-to-cat transmission was possible in confined laboratory spaces, these artificial settings are poor proxies for the natural world, she says. Just because an animal can harbor a virus in its body doesnt mean it will be good at spreading the pathogen.

Findings in domestic cats dont always translate into other species, even closely related ones. Earlier this month, a Malayan tiger named Nadia at the Bronx Zoo made headlines when she tested positive for SARS-CoV-2. Though the cause remains unclear, zoo personnel suspect an infected keeper unwittingly passed the pathogen to the tiger during routine care, triggering a dry cough and diminished appetite in the big cat. (A handful of other tigers, as well as a trio of lions, seemed slightly ill as well, but werent tested.) A vulnerable ACE2 molecule might explain Nadias spate of mild symptoms. But more than 10 million years of evolution separate domestic cats from their wild tiger kinand the two species arent always susceptible to the same diseases.

A recent mouse study reinforces the importance of ACE2 in the spread of the new virus. These rodents version of ACE2 is pretty dissimilar to ours, making them resistant to the new coronavirus; only when genetically engineered to express human ACE2 do mice fall ill. Yet other animals with less human-like variations of ACE2, including dogs and ferrets, can be vulnerable to the new coronavirus without any genetic rejiggering. ACE2 is not the whole story, Saif says.

Another influential factor in cross-species transmission is probably proximity. Even if a creatures molecular makeup isnt perfectly compatible with the pathogen, frequent exposures to humans harboring the coronavirus could eventually sicken a small percentage of the population.

This scenario may be what has played out in dogs, who seem to be poor hosts for the new coronavirus, according to the recent Science study. Some 470 million canines are kept as pets, and almost none appear to have caught SARS-CoV-2 naturally: So far, only two pupsa Pomeranian and a German shepherd, both in Hong Konghave tested positive for the pathogen.

Ferrets present a curious case as well. While their ACE2 receptors dont seem to be a perfect fit for the new coronavirus, the germ can take hold in their lungs. Researchers have known for decades that the airways of these weasel-like mammals make them susceptible to several infectious respiratory illnesses that affect humans, including the flu and the original SARS, Saif says. SARS-CoV-2, another lung-loving microbe, is no exception. Stricken with the germ, ferrets come down with fevers and coughs, helping spread the pathogen when in close contact.

Still, anatomical similarities cant fully explain why viruses find success in certain mammals. Guinea pig airways, for example, also bear some resemblance to ours, but these rodents dont always experience disease like we do. That leaves the full story of ferrets odd viral vulnerabilities somewhat mysterious, Saif says. Perhaps the ferret immune system is easily duped by the virus and struggles to purge the pathogens early on during infection.

With these preliminary findings in hand, pet owners worldwide are understandably worried about their furry family members. Sykes encourages them not to fear contagion and instead foster solidarity with our animal kin.

Its important we emphasize that human-to-human transmission is whats driving this pandemic, she says. People need to be enjoying the human-animal bond, rather than thinking about abandoning their pets.

Still, Sykes and other experts advise caution around pets, especially for owners who have reason to suspect theyve been infected with the new coronavirus. The CDC recommends treating cats and dogs as you would any other family member: self-isolating for the duration of an illness to avoid the spread of disease. Pet owners should also try to ensure their furred companions comply with physical distancing measures as much as possible, Saif adds, which means keeping them indoors and limiting contact with people and animals outside their own households.

A handful of studies have begun to survey other species for susceptibility to the new coronavirus. So far, the virus appears capable of infecting batsthe suspected original animal source of the pathogenas well as golden Syrian hamsters, but struggles to replicate in the bodies of chickens, pigs and ducks.

With more than 6,000 species of mammals inhabiting the globe, these lists are by no means comprehensive. But researchers are unlikely to get answers about other animals until they test them directly, says Smita Iyer, a virologist and immunologist at the University of California, Davis. With new viruses like these, you just dont know what you dont know.

Nevertheless, researchers have begun to take precautions against the possibility that the virus will move not from animals into humans, but the other way around. The major vector [of disease] is us, says Wellehan, who interacts with several mammalian species including bats in his work. I dont see them as a threat. I see them as potential victims.

Should humans accidentally carry SARS-CoV-2 back into the wild, the effects could be catastrophic, especially if a threatened or endangered species contracted severe disease. Concerns about our vulnerable great ape cousins, who harbor coronavirus-friendly versions of ACE2 on their cells, have already prompted conservation sites and parks to shutter.

Zoos that house wild cousins of species already shown to be vulnerable are also adopting new safety measures. At the Smithsonians National Zoo, keepers are donning extra protective equipment and practicing extensive physical distancing around primates, felids (the group that includes wild cats such as tigers, lions and cheetahs) and mustelids (relatives of ferrets, such as otters). Also being monitored are animals such as civets, the small, cat-like mammals that played a crucial role in the SARS outbreak nearly two decades ago.

Guarding these species from infection isnt an easy process, says Don Neiffer, the National Zoos chief veterinarian. Amidst a pandemic, resources are limited, he says, and some of the changes have been especially difficult for active species that spend a lot of their time engaging in play with keepers. However, Neiffer stresses, these measures are in place to maximize protection for as many species as possible for the duration of the outbreak.

By keeping wild animals safe, were also protecting ourselves. Even if most other animals dont experience severe forms of COVID-19, Saif says, they could quietly harbor the pathogen in their bodies. The virus might then be poised to reenter the human population in the future, sparking another devastating outbreak.

The breadth of the SARS-CoV-2s evolutionary reach should be an eye-opener, Iyer says. Cross-species transmissions happen in all directions: animal to animal; animal to human; and human to animal. These jumps brought us the pandemic in the first place, she says, and should be a cautionary tale for people as they continue to encroach on and destroy the worlds wild spaces.

We might want to start with the basics and respect the territory of our neighbors out in nature, Iyer says. Theres a reason theyre called wild animals.

Follow this link:
Why the New Coronavirus Affects Some Animals, but Not Others - Smithsonian

Read More...

Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today – The Motley Fool

Tuesday, April 21st, 2020

What happened

Healthcare stocks, on balance, had a great start to the week today. Cancer companies in particular posted strong gains almost across the board Monday. For instance, the stock ofClovis Oncology(NASDAQ:CLVS)ended the day up by 15.2%, shares of Immunomedics (NASDAQ:IMMU) hit a high of 10.2% before ultimately closing up by 8.5%, and Puma Biotechnology(NASDAQ:PBYI)printed a 16.3% gain today.

The odd part to this rising-tide phenomenon is that none of these companies issued a single press release or market-moving Securities and Exchange Commission filing Monday. Instead, this sea of green appears to be the result of institutional investors fleeing weaker parts of the market like oil in favor of safe havens like healthcare. Cancer stocks, after all, should be essentially immune to the economic impacts of the COVID-19 pandemic, given that most patients can't skip out on lifesaving treatments.

Image Source: Getty Images.

If this flight-to-safety thesis is true, then Clovis, Immunomedics, and Puma would arguably all make outstanding vehicles to gain exposure to the high-growth oncology space. Each of these stocks is grossly undervalued relative to its long-term value proposition. Wall Street's 12-month price targets on these names underscore this point nicely. Even after today's sizable moves, for instance, Clovis, Immunomedics, and Puma are still trading well below their 12-month price targets.

Why are these three cancer stocks undervalued right now? Clovis and Puma have both struggled to gain the confidence of investors in this volatile market due to the uncertain commercial outlook for their flagship cancer meds. Immunomedics, on the other hand, scored a major late-stage trial win with itstriple-negative breast cancer drug candidate sacituzumab govitecan earlier this year. Even so, the company's stock has yet to truly price in the full value of this positive clinical outcome, presumably because of the unfavorable market conditions in general.

Are these suddenly red-hot biotech stocks still worth buying? In a word, yes. Clovis should grab an important label expansion for its ovarian cancer med Rubraca later this year, a pivotal event that has the potential to be an inflection point for the company's commercial operations.

Puma, on the other hand, still looks like a decent buy based on the long-term commercial prospects of its breast cancer med Nerlynx. The drug's sales have been slowed down by its onerous side-effect profile, but it should nevertheless still achieve at least $300 million in annual sales. Puma's market cap, by contrast, is only $440 million at the time of this writing.

And Immunomedics stands out as a fantastic buyout target. Triple negative breast cancer is a high-value indication for which few drugs have panned out in clinical studies. Immunomedics, in turn, should fetch a healthy tender offer if sacituzumab govitecan does indeed get the green light from regulators.

See original here:
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today - The Motley Fool

Read More...

In 2003, Dr M had a plan to boost biotech in Msiabut its now a valley of ghosts – CILISOS.MY

Tuesday, April 21st, 2020

When you talk about biotechnology, some of the things that come to mind might be the Resident Evil series, Westworld, or even the Spider-man series. However, its something pretty real, and its a pretty big thing across the world.

To put it simply, biotechnology istechnology based on biology, where cellular and bio-molecular elements are used to develop technologies and products that can potentially improve our daily lives. For example, biotechnology is used to come up with medical vaccines and cures, like what theyre doing with finding a cure for the Covid-19 pandemic now.

And Malaysias apparently been paying quite a lot of attention to expand the field in the country for the last several years; were sometimes even called the biotechnology hub in Asia. And at one point in time in Malaysia

In 2003, when the 8th Malaysia Plan was announced by Dr. Mahathir Mohamad, he announced a plan to develop a BioValley as well. It was a proposal to build a localbiotechnology center in Cyberjaya, or more specifically, in Dengkil. The project served as one of the final initiatives in Mahathirs last days as our fourth Prime Minister.

While it may seem that the biotechnology buzz had just hit Malaysia around that time, it was said that our government had already identified it as one of the five key technologies to help transform Malaysia into a highly developed nation in the 1980s. According to Mahathir, this BioValley would be a 15km by 50km hard-wired zone thats intended to be a location for biotechnology innovation. Apparently, the Malaysian government at the time was hoping that the plan could attract USD$10billion in foreign and local investments within 10 years.

To develop the BioValley, our government decided to not just work with the Japanese for the architecture, but also the Massachusetts Institute of Technology (MIT). MIT had apparently recommended the BioValley focus on research into agriculture and natural resources, given that these are what we have a lot of.

Im confident we can build a multibillion dollar biotechnology industry in Malaysia. All the ingredients are here. We are just working on the recipe. MIT professor Anthony Sinskey, as quoted by The Wall Street Journal

Working together with MIT, the initial plan of the BioValley was to situate it in Dengkil with three research institutes, costing around USD$160million. And it was expected to complete in 2005. However

GIF from Gifimage.net

However, after the announcement in 2003, the plan was shrouded in mystery, where hardly anyone, especially the media, could get any details about it. For example, we didnt know anything about the progression of the project or at what stage it was in. Part of the reason behind the secrecy was said to be due to lessons learned from MSC, which didnt garner as much investment as the government had initially hoped, and the government wascautioned against overselling the BioValley project.

We want to get the project off the ground rather than talk about it. An official at the Science, Technology and Environment Ministry, as quoted by Nature

What we do know is that apparently, there were already three companies that had agreed to park themselves in the BioValleyin 2003, and the government was in the process of negotiating with another 20. Not just that, while it was still in planning stages, researchers were already tapping into our countrys resources, such as looking into tongkat ali to treat, um, certain disabilities in men.

Following the announcement of the BioValley in 2003, Mahathir resigned and Abdullah Ahmad Badawi took over as our fifth Prime Minister, so essentially, he took over the project as well.

However, the expected completion date of 2005 cameand went. Until today, theres still nothing to show for the BioValley. There currently are no photos or anything of the BioValley that was supposedly to be already under development.

Now, there are different verdicts about the BioValley project. Some have claimed that its still under development, some said that its never existed, while others just dont want to talk about it. We dont even know for sure where the USD$160million that was supposed to go into the project had gone to. All thats left is apparently an 80-hectare construction site with a few empty buildings in Dengkil, but even then, theres no pictures of the site.

One had even called it

It was one of the most grandiose biotechnology projects. We were hoping that BioValley would take off. University of Malaya Research & Innovation Assistant Vice-Chancellor Rofina Yasmin Othman, as quoted by Malaysian Business

But thats not to say that weve completely failed in our biotechnology ventures as

Image from EduSpiral

While the BioValley kinda didnt pan out, we still have a pretty strong presence within the industry. Malaysia was ranked fourth globally for Biotech Enterprise Support in the Scientific American Report and second in ASEAN for intellectual property protection in the IMD World Competitiveness Index Yearbook.

Plus, our government launched aNational Bioeconomy Programmein 2010, making Malaysia the first in Southeast Asia to have such an initiative. The main objectives were to focus on specific bio-based industries in Malaysia in order turn Malaysia into a high-income nation bywell, this year, actually.

In fact, biotechnology has become so important in Malaysia that we came up with our Biosafety Act to regulate the release, importation, exportation and contained use of living modified organisms, and the release of products of such organisms. And that also made us one of the few Asian countries to be activelymanaging and assessing the risks that come with biotechnology.

And when we talk about the BioValley, while the BioValley in Dengkil doesnt seem to be operational any time soon, wedohave a BioValley of a smaller scale in Miri, Sarawak, funded by the Sarawak government.

Its not the same thing as the one in Dengkil, but hey, at least its something! Its a collaboration between the Sarawak government and Curtin University. Just like the plan for the initial BioValley in Dengkil, this ones meant to support the development and research of biotechnology, while also providing jobs.

The Sarawak Biovalley Pilot Plant is unique because it aims to assess and maximise the viability of bio-products for commercial production. Curtin University Malaysia pro vice-chancellor Jim Mienczakowski, as quoted by NST

As of the BioValley project in Dengkil, well, a PPBM supreme council member had suggested that the production of ketum and cannabiscan help in reviving it, but thats simply a suggestion. For now, theres been no further news on the BioValley project in Dengkil. When Mahathir returned for his second run as Prime Minister, he didnt say a word about it either.

But all things considered, weve managed to attract major players in the industry into Malaysia. Not just that, Malaysia itself has also been doing pretty well with our own research institutes to boost biotechnology. So it does seem that theres still a pretty bright future for biotechnology in Malaysia.

View post:
In 2003, Dr M had a plan to boost biotech in Msiabut its now a valley of ghosts - CILISOS.MY

Read More...

Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results – GlobeNewswire

Tuesday, April 21st, 2020

SOUTH SAN FRANCISCO, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report first quarter 2020 financial results on Thursday, May 7, 2020, after the close of the market.

Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will host a conference call and webcast at 2:30 p.m. PT / 5:30 p.m. ET on May 7, 2020, to discuss first quarter 2020 financial results and operational progress. A press release outlining the financial results will be publicly distributed before the call.

Individuals interested in listening to the conference call may do so by dialing:

US domestic callers: (877) 556-5248Outside US callers: (720) 545-0029Please reference Conference ID: 6873327

A live webcast of the conference call will be available online from the Investor Relations page of the Companys website at Events & Presentations. The link will not be active until 2:15 p.m. PT / 5:15 p.m. ET on May 7, 2020.

After the live webcast, the call will be archived on Fluidigms Investor Relations page at investors.fluidigm.com. In addition, a telephone replay of the teleconference will be available approximately 90 minutes after the end of the call.

The replay dial-in numbers are:

US domestic callers: (855) 859-2056Outside US: (404) 537-3406Please reference Conference ID: 6873327

The telephone replay will be available until May 14.

About Fluidigm Fluidigm (Nasdaq:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOFand microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.

Fluidigm, theFluidigmlogo, and CyTOF are trademarks and/or registered trademarks ofFluidigm Corporationinthe United Statesand/or other countries.Fluidigmproducts are provided for Research Use Only. Not for use in diagnostic procedures.

Available InformationWe use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases,SECfilings, public conference calls, and webcasts.

Contact:

Agnes LeeVice President, Investor RelationsFluidigm Corporation650 416 7423agnes.lee@fluidigm.com

Read this article:
Fluidigm Announces Conference Call and Webcast of First Quarter 2020 Financial Results - GlobeNewswire

Read More...

Puma Biotechnology Inc. [PBYI] Analyzing the PBYI using Fundamentals and Trend Analysis – The Dwinnex

Tuesday, April 21st, 2020

Puma Biotechnology Inc. [NASDAQ: PBYI] shares went higher by 12.21% from its previous closing of 8.60, now trading at the price of $9.65, also adding 1.05 points. Is PBYI stock a buy or should you stay away?

The stock had a rather active trading session with the latest closing, by far recording 1.09 million contracts. Compared to the average trading volume of PBYI shares, the company saw a far better performance. Moreover, the stock has a 34.74M float and a 20.78% run over in the last seven days. PBYI share price has been hovering between 35.27 and 5.50 lately, and is definitely worthy of attention.

Professional stock traders oftentimes make sure they verify what some leading Wall Street voices have to say about a potential buy. Currently, in relation to Puma Biotechnology Inc. [PBYI], the latest Wall Street average recommendation we can view is from the fiscal quarter that will be ending in the month of 12/30/2019. On average, stock market experts give PBYI an Hold rating. The average 12-month price forecast for this stock is $9.65, with the high estimate being $15.00, the low estimate being $6.00 and the median estimate amounting to $13.50. This is compared to its latest closing price of $8.60.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Puma Biotechnology Inc. [PBYI] is sitting at 3.00. This is compared to 1 month ago, when its average rating was 3.00.

Keep on the lookout for this organizations next scheduled financial results, which are expected to be made public on 05/06/2020.

Now lets turn to look at profitability: with a current Operating Margin for Puma Biotechnology Inc. [PBYI] sitting at -23.30% and its Gross Margin at 86.50%, this companys Net Margin is now -27.80. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.

This companys Return on Total Capital is -24.14, and its Return on Invested Capital has reached -47.06. Its Return on Equity is -302.70%, and its Return on Assets is -29.10%. These metrics suggest that this Puma Biotechnology Inc. does a poor job of managing its assets, and likely wont be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organizations capital structure, Puma Biotechnology Inc. [PBYI] has generated a Total Debt to Total Equity ratio of 688.48. Similarly, its Total Debt to Total Capital is 87.32, while its Total Debt to Total Assets stands at 51.18. Looking toward the future, this publicly-traded companys Long-Term Debt to Equity is 673.45, and its Long-Term Debt to Total Capital is 85.41.

What about valuation? This companys Enterprise Value to EBITDA is -9.35. The Enterprise Value to Sales for this firm is now 1.07, and its Total Debt to Enterprise Value stands at 0.35. Puma Biotechnology Inc. [PBYI] has a Price to Book Ratio of 19.64, a Price to Cash Flow Ratio of 15.16.

Puma Biotechnology Inc. [PBYI] has 38.22M shares outstanding, amounting to a total market cap of 368.82M. Its stock price has been found in the range of 5.50 to 35.27. At its current price, it has moved down by -72.64% from its 52-week high, and it has moved up 75.45% from its 52-week low.

This stocks Beta value is currently 1.21, which indicates that it is 9.49% more volatile that the wider market. This stocks Relative Strength Index (RSI) is at 56.30. This RSI score is good, suggesting this stock is neither overbought or oversold.

Shares of Puma Biotechnology Inc. [PBYI], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this companys financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.

Visit link:
Puma Biotechnology Inc. [PBYI] Analyzing the PBYI using Fundamentals and Trend Analysis - The Dwinnex

Read More...

Does Apex Biotechnology Corp.s (TPE:1733) 20% Earnings Growth Make It An Outperformer? – Simply Wall St

Tuesday, April 21st, 2020

Measuring Apex Biotechnology Corp.s (TSEC:1733) track record of past performance is an insightful exercise for investors. It enables us to reflect on whether the company has met or exceed expectations, which is a powerful signal for future performance. Below, I will assess 1733s recent performance announced on 31 December 2019 and compare these figures to its historical trend and industry movements.

Check out our latest analysis for Apex Biotechnology

1733s trailing twelve-month earnings (from 31 December 2019) of NT$114m has jumped 20% compared to the previous year.

Furthermore, this one-year growth rate has exceeded its 5-year annual growth average of -28%, indicating the rate at which 1733 is growing has accelerated. Whats enabled this growth? Lets take a look at if it is merely due to industry tailwinds, or if Apex Biotechnology has experienced some company-specific growth.

In terms of returns from investment, Apex Biotechnology has fallen short of achieving a 20% return on equity (ROE), recording 6.7% instead. Furthermore, its return on assets (ROA) of 4.3% is below the TW Medical Equipment industry of 6.2%, indicating Apex Biotechnologys are utilized less efficiently. And finally, its return on capital (ROC), which also accounts for Apex Biotechnologys debt level, has declined over the past 3 years from 12% to 9.3%. This correlates with an increase in debt holding, with debt-to-equity ratio rising from 21% to 29% over the past 5 years.

Apex Biotechnologys track record can be a valuable insight into its earnings performance, but it certainly doesnt tell the whole story. Recent positive growth isnt always indicative of a continued optimistic outlook. There may be factors that are impacting the industry as a whole, thus the high industry growth rate over the same time period. You should continue to research Apex Biotechnology to get a better picture of the stock by looking at:

NB: Figures in this article are calculated using data from the trailing twelve months from 31 December 2019. This may not be consistent with full year annual report figures.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.

View post:
Does Apex Biotechnology Corp.s (TPE:1733) 20% Earnings Growth Make It An Outperformer? - Simply Wall St

Read More...

Stem-cell therapy in Moscow attracting patients from West …

Monday, April 20th, 2020

Every three months, David Martin, a quadriplegic, returns to a small clinic here in the Russian capital for therapy he cannot legally get back home in Kalamazoo, Mich.: injections of stem cells taken from his own body, at a cost of $12,000 per visit.

MOSCOW Every three months, David Martin, a quadriplegic, returns to a small clinic here in the Russian capital for therapy he cannot legally get back home in Kalamazoo, Mich.: injections of stem cells taken from his own body, at a cost of $12,000 per visit.

Martins U.S. doctors have tried to dissuade him from believing any improvement in his condition could be the byproduct of stem-cell treatments, a therapy not yet approved in the United States. No scientific evidence has ever shown that such treatments can repair human spinal-cord injuries, experts say.

Yet Martin notices glints of progress a twinge of sensation in one of his curled, still hands, a faraway feel of something cold on his skin. He attributes it to the stem-cell treatments he has been getting in Moscow.

Its definitely unfortunate that the U.S. isnt doing this, said Martin, 36, paralyzed since a car accident in 2006. Its not an inexpensive venture, and its not easy on the body to have to travel this distance.

Martin is just one of a growing number of Americans and Europeans turning to Russia, China and other countries where the stem-cell industry operates unfettered and largely unregulated.

NeuroVita, the clinic Martin has been visiting since 2007, attracts paraplegics and quadriplegics from around the world and maintains a waiting list for overflow clientele. Elsewhere in the capital, chic beauty clinics rely on stem-cell therapy to beckon Moscows moneyed elite, pitching the treatments as a surefire answer to wrinkles and stretch marks.

What troubles critics is the rush in some countries to offer stem-cell therapy on the health-care market, the absence of governmental oversight associated with stem-cell treatments in those countries, and the lack of any proof that the treatments actually work. If patients feel improvement, experts say, its likely a placebo effect or the result of their bodys own healing mechanisms.

NeuroVita relies on adult stem cells taken from the patients own bone marrow, a type of stem cell widely regarded as having far less therapeutic potential than embryonic stem cells stem cells derived from human embryos.

About making money

While adult stem cells may be useful in treating cancer or brittle-bone disease, most experts think its impossible to turn blood-derived adult stem cells into nerve cells, and that anyone offering such treatments is not relying on peer-reviewed science.

I dont think theres much science to it, said Vladimir Smirnov, director of the Moscow Institute of Experimental Cardiology, a licensed Russian stem-cell researcher and a leading critic of clinics that sell stem-cell injections. Its all about making money.

The wonder of stem cells lies in their ability to reproduce and differentiate into whatever variety of tissue the body requires. Adult cells do not reproduce, but stem cells divide freely. Stem cells also tend to seek out damaged tissue, making them catalysts for restoration. In recent years, scientists have been encouraged by research that suggests stem-cell therapy could one day be applied to a wide array of disorders and injuries.

A recent study involving rats with Parkinsons disease showed that embryonic stem cells genetically altered to yield dopamine-producing neurons could be transplanted into the rats brains and improve motor function. Other studies have shown that adult stem cells injected into mice with damaged hearts can repopulate heart tissue with new heart-muscle cells.

Doctors have been relying for four decades on bone-marrow transplants that use adult stem-cell technology to treat cancers such as leukemia and lymphoma.

But the U.S. Food and Drug Administration (FDA) has yet to approve embryonic or adult stem-cell injections to treat other disorders. The FDA allows stem-cell clinical trials involving humans, but the research is carefully controlled and usually involves a small number of patients.

Elsewhere in the world, however, regulations governing stem-cell therapy are lax and usually poorly enforced.

In Russia, the Federal Health Inspection Service must approve a clinics use of stem-cell therapy. Several years ago, Russian authorities shut down more than 30 medical institutions illegally carrying out stem-cell treatments, but numerous clinics continue to sell the injections under the radar of regulators.

Clinical trials allowed

A Moscow clinic called Beauty Plaza has the governments permission to carry out adult stem-cell injections within the framework of clinical trials. The stem cells are taken from the patients fatty tissue. Usually, subjects of clinical trials do not pay for their treatments, but Beauty Plaza clients have to pay for theirs, says the clinics director, Alexander Teplyashin.

We can eradicate atherosclerosis symptoms, and we can cure diabetes Type 2, Teplyashin said confidently during an interview at his clinic. After the treatments, patients stop getting the flu. They become more energetic, more active.

According to its Web site, NeuroVita has governmental approval to offer adult stem-cell therapy to neurological patients. The clinics director, Andrei Bryukhovetsky, said NeuroVita has used stem-cell treatments on 200 patients since 2002, 70 percent of them foreign citizens and at least 30 patients from the United States.

Bryukhovetsky touts results that most experts would label as doubtful: A young man from Siberia paralyzed from the neck down now eats on his own, drinks tea, all within a year. For another patient with a spinal-cord injury in his neck, one injection was enough. After one day he began writing, Bryukhovetsky said.

How can we explain it? I dont know, Bryukhovetsky said. But it works.

The trouble with such anecdotal evidence, said Evan Snyder, a U.S. expert on stem-cell research, is that it lacks credibility. And the best environment to ensure that credibility, Snyder said, is a proper, well-controlled clinical trial.

Anecdotal evidence doesnt mean anything to me, said Snyder, a stem-cell researcher at the Burnham Institute in La Jolla, Calif. Im happy for the patient if he feels better. But one has to be cautious about what to attribute that improvement to.

Stem-cell treatments arent without risk, Snyder adds.

It could be a situation where the stem cells go to the wrong place in the body, or they are the wrong type of cells for a given region, he said. They could turn into cancer themselves, or cause neighboring cells to become cancerous.

It remains unclear when stem-cell technology will be ready for broader application in U.S. health care. Patients like Martin say they dont want to wait.

Patient sees progress

On a recent afternoon in a physical-therapy room at NeuroVita, Martin demonstrated what he believed was progress attributable to the stem-cell injections he received in his spine. He winced slightly as his hands, fastened to weight machine handles with leather straps, pulled back to lift 55 pounds. Before the treatments, he could lift just 2 pounds, he said.

Ive come a long way, Martin said. Seems like every time I come back from Russia, Ive gone up 5 or 10 pounds.

Martin, manager of an automotive component plant before the accident, spent $33,000 on an initial visit, for an overall cost of about $81,000 on five visits to NeuroVita since June 2007.

He believes hell need one more year of treatments.

If someone has the wherewithal to do something like that and it improves their psychological well-being, I wouldnt prevent them from doing it, said, Snyder the stem-cell researcher, as long as they recognized that the likelihood for improvement is minimal.

Follow this link:
Stem-cell therapy in Moscow attracting patients from West ...

Read More...

Stem Cell Umbilical Cord Blood Market 2020 Share Insights and Dynamics | Cells for Life, Cryolife, Cryo-Cell Cole Reports – Cole of Duty

Monday, April 20th, 2020

Futuristic Reports, The growth and development of Global Stem Cell Umbilical Cord Blood Market Report 2020 by Players, Regions, Type, and Application, forecast to 2026 provides industry analysis and forecast from 2020-2026. Global Stem Cell Umbilical Cord Blood Market analysis delivers important insights and provides a competitive and useful advantage to the pursuers. Stem Cell Umbilical Cord Blood processes, economic growth is analyzed as well. The data chart is also backed up by using statistical tools.

Simultaneously, we classify different Stem Cell Umbilical Cord Blood markets based on their definitions. Downstream consumers and upstream materials scrutiny are also carried out. Each segment includes an in-depth explanation of the factors that are useful to drive and restrain it.

Key Players Mentioned in the study are Cell Care, Cells for Life, Cryolife, Cryo-Cell, CBR (Cord Blood Registry), Stemlife, CELLTREE(CELLTREE), StemOne Biologicals, Healthbanks Biotech, Stemcyte Inc, Smart Cells, ViaCord, LifeCell, Cryosite, Cordlife

For Better Understanding, Download FREE Sample Copy of Stem Cell Umbilical Cord Blood Market Report @ https://www.futuristicreports.com/request-sample/39381

Key Issues Addressed by Stem Cell Umbilical Cord Blood Market: It is very significant to have Stem Cell Umbilical Cord Blood segmentation analysis to figure out the essential factors of growth and development of the market in a particular sector. The Stem Cell Umbilical Cord Blood report offers well summarized and reliable information about every segment of growth, development, production, demand, types, application of the specific product which will be useful for players to focus and highlight on.

Businesses Segmentation of Stem Cell Umbilical Cord Blood Market:

On the basis on the applications, this report focuses on the status and Stem Cell Umbilical Cord Blood outlook for major applications/end users, sales volume, and growth rate for each application, including-

Blood Disorders Cancers Immune Disorders Metabolic Disorders Others

On the basis of types/products, this Stem Cell Umbilical Cord Blood report displays the revenue (Million USD), product price, market share, and growth rate of each type, split into-

Allogeneic stem cell umbilical cord blood Autologous stem cell cord blood

Grab Best Discount on Stem Cell Umbilical Cord Blood Market Research Report [Single User | Multi User | Corporate Users] @ https://www.futuristicreports.com/check-discount/39381

NOTE: Our team is studying Covid-19 impact analysis on various industry verticals and Country Level impact for a better analysis of markets and industries. The 2020 latest edition of this report is entitled to provide additional commentary on latest scenario, economic slowdown and COVID-19 impact on overall industry. Further it will also provide qualitative information about when industry could come back on track and what possible measures industry players are taking to deal with current situation.

OR

You just drop an Email to: [emailprotected] us if you are looking for any Economical shift towards the New Normal on any Country or Industry Verticals.

Stem Cell Umbilical Cord Blood Market Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) North America (the United States, Mexico, and Canada.) South America (Brazil etc.) The Middle East and Africa (GCC Countries and Egypt.)

Stem Cell Umbilical Cord Blood Insights that Study is going to provide:

Gain perceptive study of this current Stem Cell Umbilical Cord Blood sector and also possess a comprehension of the industry; Describe the Stem Cell Umbilical Cord Blood advancements, key issues, and methods to moderate the advancement threats; Competitors In this chapter, leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue. A separate chapter on Stem Cell Umbilical Cord Blood market structure to gain insights on Leaders confrontational towards market [Merger and Acquisition / Recent Investment and Key Developments] Patent Analysis** Number of patents filed in recent years.

Table of Content:

Global Stem Cell Umbilical Cord Blood Market Size, Status and Forecast 20261. Market Introduction and Market Overview2. Industry Chain Analysis3. Stem Cell Umbilical Cord Blood Market, by Type4. Stem Cell Umbilical Cord Blood Market, by Application5. Production, Value ($) by Regions6. Production, Consumption, Export, Import by Regions (2016-2020)7. Market Status and SWOT Analysis by Regions (Sales Point)8. Competitive Landscape9. Analysis and Forecast by Type and Application10. Channel Analysis11. New Project Feasibility Analysis12. Market Forecast 2020-202613. Conclusion

Enquire More Before Buying @ https://www.futuristicreports.com/send-an-enquiry/39381

For More Information Kindly Contact:

Futuristic ReportsTel: +1-408-520-9037Media Release: https://www.futuristicreports.com/press-releases

Follow us on Blogger @ https://futuristicreports.blogspot.com/

See original here:
Stem Cell Umbilical Cord Blood Market 2020 Share Insights and Dynamics | Cells for Life, Cryolife, Cryo-Cell Cole Reports - Cole of Duty

Read More...

Astronomers observe the brightest supernova on record – Yahoo Lifestyle

Monday, April 20th, 2020

In 2016, astronomers spotted the brightest supernova ever observed. They watched as the supernova, named SN2016aps, continued to emit radiation for more than 1,000 days. Today, in a paper published in Nature, they describe how this extremely energetic supernova could help them understand the universes evolution and the formation of the most massive stars.

SN2016aps flared so brightly that it outshone its own galaxy, and over its long span, it emitted more light than any supernova on record, Matt Nicholl, the studys first author from the University of Birmingham in the United Kingdom, told Gizmodo. At five to 10 times the mass of a typical supernova, it was one of the largest stars ever seen to explode. The total mass of the object and the material it ejected before exploding could have been 50 to 100 times the mass of the Sun, Gizmodo notes.

SN2016aps likely occurred around 10 billion years after the Big Bang. Now, with data from this supernova and more powerful telescopes like the James Webb Space Telescope, the researchers hope to find similar events even further back in the universes history, when they may have been more common.

See more here:
Astronomers observe the brightest supernova on record - Yahoo Lifestyle

Read More...

The bodies of COVID-19 victims may be contagious, coroner’s case reveals – Livescience.com

Monday, April 20th, 2020

Even after death, COVID-19 could be contagious, a new report finds.

A forensic practitioner working in Bangkok, Thailand, most likely caught the virus from a deceased patient, according to the report, which was posted online April 11 as a preprint for the Journal of Forensic and Legal Medicine.

The forensic practitioner later died of the virus, marking the first case on record of a "COVID-19 infection and death among medical personnel in a forensic medicine unit," the researchers wrote in the report.

Related: Latest COVID-19 news and US case counts

At the time the report was written on March 19, just 272 people in Thailand including the forensic practitioner and a nurse assistant had tested positive for the new coronavirus. Most of these cases were imported, meaning they weren't from community spread, the researchers wrote. So, it's unlikely that the forensic practitioner caught the new coronavirus outside of work or even from a patient at the hospital, the researchers wrote.

"There is [a] low chance of forensic medicine professionals coming into contact with infected patients, but they can have contact with biological samples and corpses," the researchers wrote in the report.

It's not surprising that the body of a recently deceased COVID-19 patient might be contagious, said Dr. Otto Yang, a professor in the Department of Medicine and the Department of Microbiology, Immunology and Molecular Genetics at the David Geffen School of Medicine at UCLA.

"Absolutely, a dead body would be contagious at least for hours if not days," Yang told Live Science in an email. "The virus will still be in respiratory secretions, and potentially still reproducing in cells that haven't yet died in the lungs."

COVID-19's longevity in the body can be problematic for people in the funerary industry. For instance, following reports that temples in Thailand were refusing to perform funeral services of COVID-19 victims, the head of Thailand's Department of Medical Services incorrectly announced on March 25 that the disease was not contagious in bodies after death, according to Buzzfeed News.

It's unclear, however, just how long the virus remains infectious in a dead body.

In light of this finding, forensic scientists should take a number of precautions while examining the remains of COVID-19 patients, the researchers said. For instance, forensic professionals should wear protective gear, including a protective suit, gloves, goggles, a cap and a mask, they wrote.

"The disinfection procedure used in operation rooms might be applied in pathology/forensic units too," they added.

Usually, pathogens that kill people don't survive long enough to spread to others after the person's death, according to the World Health Organization (WHO). "Human remains only pose a substantial risk to health in a few special cases, such as deaths from cholera or haemorrhagic fevers," such as Ebola, the WHO said.

Other illnesses that are contagious in human remains include tuberculosis, bloodborne viruses (such as hepatitis B and C and HIV) and gastrointestinal infections (including E. coli, hepatitis A, Salmonella infection and typhoid fever), according to the WHO.

Originally published on Live Science.

Read the original here:
The bodies of COVID-19 victims may be contagious, coroner's case reveals - Livescience.com

Read More...

The fundamentalsof fertility in beef cattle – Farmer’s Weekly

Monday, April 20th, 2020

A livestock farmer is firstly a veld and pasture farmer. It is vital that the animals nutritional requirements are met, especially during breeding and when the cows are raising calves.

Moreover, the cattle should be fully fed in a relatively short period of grazing. This implies that the farms fodder flow must be sufficient throughout the year.

Arguably the most crucial aspect of grazing management after establishing the correct stocking rate is to ensure that a portion of the veld and pasture is given a periodic rest period comprising a full growing season.

The foremost economic factor of a cattle farming enterprise is fertility. It is five times more important than growth performance, which in turn is five times more important than carcass quality. Obviously, it is better to have a poorly performing calf than no calf at all.

Management & geneticsFertility has both a management and a genetic component. The management component includes all those aspects, such as feeding correctly and maintaining animal health, that are your sole responsibility as a farmer.

It also includes maintaining strict breeding seasons in order to establish which animals are not reproducing. Breeding seasons make it far easier for you to use a veterinarian to determine which cows have failed to conceive.

Good management enables animals to produce and reproduce optimally. The genetic component of fertility is limited to 10% heritability. However, it is highly repeatable, so make sure to identify the cow families that calve every year.

Just to be clear: heritability is a reflection of the degree to which offspring performance is a reflection of the performance of their parents.

Repeatability is a measure of the strength of the relationship between repeated records. As a producer, knowing the repeatability of a trait can help you make culling decisions. You can also use repeatability as a measurement to predict early on how productive a cow will be over her lifetime in terms of milk production and calf weaning.

Breeding valuesSelect for genetic traits that are positively correlated with fertility, such as scrotal size and mature body mass, and consider the fertility index itself, such as days to calving. These are expressed as estimated breeding values (EBVs).

Remember, however, that if the animals feed and other requirements are not met, you cannot correct for this by selecting for higher fertility on a genetic level.

Scrotal size in bulls plays a major role in determining the fertility of the female offspring. It is true that bigger is better, but only up to a point. Look at the scrotal size or scrotal circumference EBVs of the bulls you buy, and physically examine scrotal development. Two equally well-developed testes with good epididymis development are very important.

Another key trait is mature weight, which should always be kept in check. The EBV for mature weight should ideally be around breed average. Your aim should be to breed cows that calve easily and produce fast-growing calves, but you dont want breeding stock that are too large by the time they wean their first calf, because big cattle have high maintenance requirements. Moreover, animals that are heavy at maturity are often less productive.

The days-to-calving fertility index identifies bulls and cows that carry the genes producing fertile progeny. Animals that take less time to calve from the initial mating date have a better days-to-calving index and are thus more fertile.

This index also plays a large part in the overall economic indices for certain systems, such as a self-replacing feedlot.

Bull selectionA bull has a 50% genetic influence on a herd of females that he gets into calf. Its therefore crucial to buy and use bulls with the correct fertility and growth attributes. The old adage, A good bull is half your herd and a bad bull is your whole herd, holds true.

Be sure to maintain the correct bull-to-cow ratio and to test bulls regularly for fertility and sexually transmitted diseases.

As a general guideline, a two-year-old bull should be able to cope with 20 females in a two- to three-month breeding season. At three years old, a bull should service 30 females within this time frame, and by four years, he should be able to breed with 40 females.

Early calvers are generally the more fertile animals. The shorter you make your calving season, the more fertile your herd will become. Ideally, 60% of your females should calve in the first 30 days of the season. By selling your late calvers, you also in effect shorten your breeding season.

CrossbreedingHybrid vigour increases fertility, growth and longevity, so it pays to crossbreed. But this must be carried out in a structured way, and good management is essential. A normal crisscrossing system or a three-way cross system can be followed.

It is also very important to choose a breed or type of cattle that is suited to your environment and farming system.

Under more extensive conditions (in large parts of the country), breeds with a certain mix of Bos taurus (for production) and B. indicus (for hardiness and adaptability) demonstrate greater fertililty. Under more intensive and higher-rainfall systems, B. taurus-type breeds do better.

Under extremely arid and hot conditions where the stocking rate is very low, indigenous B. indicus-type cattle and Brahmans fare best.

Email Llewellyn Angus at [emailprotected].

More here:
The fundamentalsof fertility in beef cattle - Farmer's Weekly

Read More...

Page 14«..10..13141516..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick